ArticleInternational journal of colorectal disease2025
Inverse effects of lymph node count on oncological outcomes in rectal cancer based on lymph node positivity status post-neoadjuvant CRT: a large-volume Chinese center experience.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stratified lymph node yield thresholds after neoadjuvant immunochemotherapy: a surgical benchmark for survival in oral squamous cell carcinoma.Frontiers in immunology · 2026Article
- Effect of lymph node dissection numbers after conversion immunochemotherapy on the survival of gastric cancer patients: a multi-center retrospective study.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeoadjuvant chemoradiation therapy (CRT) followed by total mesorectal excision (TME) is the standard of care for locally advanced rectal cancer (LARC). Current guidelines recommend dissecting at least 12 lymph nodes (LNs). However, the impact of LN count post-CRT on survival outcomes remains controversial. This study aimed to evaluate the relationship between LN count and oncologic outcomes in LARC patients treated with neoadjuvant CRT followed by surgery.
methodsThis retrospective analysis was conducted on 1483 patients with cT3-4N + LARC who underwent neoadjuvant CRT and curative resection. Univariate and multivariate analyses were performed to identify factors associated with achieving 12 or more LNs. Restricted cubic spline (RCS) and Cox proportional hazards models were used to assess the relationship between LN count and oncologic outcomes, including disease-free survival (DFS) and overall survival (OS). Exploratory subgroup analyses stratified patients by ypN positivity status.
resultsThe mean number of LNs retrieved was 12.9 ± 6.8, with 55.7% of patients having 12 or more LNs examined. Laparoscopic surgery, tumor location (mid rectum), younger age, and lymph node status (pN2) were independent factors associated with achieving 12 or more LNs. RCS analysis revealed an inverse relationship between LN count and tumor response to CRT, but no association with OS and DFS in the overall cohort. ypN-negative patients tended to have a higher rate of liver metastases with an increased LN count (P = 0.010). However, in ypN-positive patients, a higher LN count was associated with improved DFS (P = 0.007) and a lower likelihood of lung metastases (P = 0.001). Using X-tile software, a cutoff value of 10 LNs was identified as optimal for DFS in stage 3 rectal cancer patients. Patients with 11 or more LNs examined had significantly better 5-year DFS (66.7% vs. 55.8%, P = 0.035) compared to those with fewer than 11 LNs.
conclusionOur study challenges the guideline of examining at least 12 LNs during rectal cancer surgery after CRT, as we observed an inverse relationship between LN count and tumor response to CRT. The inverse effects of LN count on oncological outcomes across various stages of LN positivity highlight the need for individualized treatment strategies based on lymph node positivity status. For ypN-negative patients, understanding that an increased LN count is associated with a higher risk of liver metastases can help identify high-risk stage 0-2 patients who may benefit from adjuvant therapy. For ypN-positive (stage 3) patients, achieving at least 11 LNs is necessary to ensure better oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.